IRBM helps biotech and pharma teams de-risk complex drug discovery, advancing programs from early research through preclinical development. Clients can run a full integrated program or draw on standalone services, with go/no-go criteria agreed before the work starts, so a series that cannot reach the target profile is stopped early.
What we can run for you
- Small molecules: medicinal, synthetic and computational chemistry, compound management and screening libraries
- Peptides: peptide chemistry, macrocyclic peptides, complex peptides and proteins
- Antibodies and display technologies: antibody discovery and characterization, peptide and antibody phage display, mRNA display
- Biosciences: assay development, high throughput and high content screening, biophysical approaches, functional genomics
- Structural biology: NMR and protein production
- DMPK and in vivo: ADME and pharmacology, PK, PD and bioanalytics, in vivo pharmacology
- Therapeutic areas: oncology and immuno-oncology, neuroscience, infectious disease, rare diseases
Track record
- Three marketed drugs to which our scientists directly contributed
- 30+ preclinical candidates delivered
- 100+ patents attributed to IRBM scientists
- 15+ years of repeat partnerships
One team, one site. All R&D runs at a single research campus of about 80,000 m² near Rome, Italy, founded as a Merck Research Laboratories site and independent since 2010. Chemistry, biology, DMPK, in vivo pharmacology and structural biology sit in the same building and meet on the same program, which means seamless handovers between disciplines and faster turnaround. Every project has a dedicated project representative as a single point of contact, and you talk to the scientists doing the work.
Start a conversation with our scientists | Download the IRBM discovery overview (PDF)